首页> 外文期刊>Current opinion in pharmacology >Maximizing serendipity: strategies for identifying ligands for orphan G-protein-coupled receptors.
【24h】

Maximizing serendipity: strategies for identifying ligands for orphan G-protein-coupled receptors.

机译:最大化偶然性:识别孤儿G蛋白偶联受体配体的策略。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

G-protein-coupled receptors (GPCRs) represent the largest family of cell-surface receptors within the human genome, and historically these have been a rich source of targets for small-molecule modulation and therapeutic intervention. As a result of genome closure, numerous novel GPCRs that have unknown ligands and function were identified, and termed 'orphans'. These are considered potential new targets for drug discovery, and many companies have been focusing on ligand identification using high-throughput functional assays in the quest to discover a tool to further probe the pathophysiolgical role of these new receptors. In the past five years, approximately 50 receptors have been ligand-paired, although putative functions have only been described for the minority. The number of new small-molecule modulators that ultimately make it to the market will measure the success of this initiative.
机译:G蛋白偶联受体(GPCR)代表了人类基因组中最大的细胞表面受体家族,从历史上看,它们一直是小分子调节和治疗干预目标的丰富来源。作为基因组封闭的结果,鉴定了许多具有未知配体和功能的新颖GPCR,并将其称为“孤儿”。这些被认为是潜在的新药物发现靶标,并且许多公司一直致力于使用高通量功能测定法进行配体鉴定,以寻求发现进一步探查这些新受体的病理生理作用的工具。在过去的五年中,大约50个受体已被配体配对,尽管假定功能仅针对少数人进行了描述。最终推向市场的新型小分子调节剂的数量将衡量该计划的成功。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号